Compare LCNB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | BCYC |
|---|---|---|
| Founded | 1877 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 256.5M |
| IPO Year | 1999 | 2019 |
| Metric | LCNB | BCYC |
|---|---|---|
| Price | $19.57 | $3.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $20.83 | $9.17 |
| AVG Volume (30 Days) | 19.2K | ★ 402.9K |
| Earning Date | 10-15-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $11.08 | N/A |
| Revenue Next Year | $0.51 | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.83 | $3.33 |
| 52 Week High | $21.32 | $7.83 |
| Indicator | LCNB | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 49.35 |
| Support Level | $18.44 | $3.44 |
| Resistance Level | $20.29 | $4.08 |
| Average True Range (ATR) | 0.47 | 0.20 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 35.37 | 36.11 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.